Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
CTLA-4 Antigen
/ immunology
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Cycle Checkpoints
/ immunology
Drug Evaluation, Preclinical
Humans
Immunologic Factors
/ therapeutic use
Immunotherapy
/ methods
Programmed Cell Death 1 Receptor
/ immunology
Triple Negative Breast Neoplasms
/ drug therapy
Breast cancer
CTLA-4
Immune checkpoint inhibitor
PD-1
PD-L1
Preclinical model
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
06
07
2019
accepted:
17
08
2019
pubmed:
14
10
2019
medline:
29
5
2020
entrez:
14
10
2019
Statut:
ppublish
Résumé
The Food and Drug Administration has lately approved atezolizumab, anti-programmed death ligand 1 (PD-L1), to be used together with nanoparticle albumin-bound (nab) paclitaxel in treating patients with triple negative breast cancer (BC) expressing PD-L1. Nonetheless, immune checkpoint inhibitors (ICIs) are still challenged by the resistance and immune-related adverse effects evident in a considerable subset of treated patients without conclusive comprehension of the underlying molecular basis, biomarkers and tolerable therapeutic regimens capable of unleashing the anti-tumour immune responses. Stepping back to preclinical models is thus inevitable to address these inquiries. Herein, we comprehensively review diverse preclinical models of BC exploited in investigating ICIs underscoring their pros and cons as well as the learnt and awaited lessons to allow full exploitation of ICIs in BC therapy.
Identifiants
pubmed: 31606656
pii: S0959-8049(19)30473-3
doi: 10.1016/j.ejca.2019.08.013
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
CTLA-4 Antigen
0
Immunologic Factors
0
Programmed Cell Death 1 Receptor
0
atezolizumab
52CMI0WC3Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
22-41Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.